Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study)
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The use of noninsulin antihyperglycaemic drugs in the hospital setting has not yet been fully described. This observational study compared the efficacy and safety of the standard basal-bolus insulin regimen versus a dipeptidyl peptidase-4 inhibitor (linagliptin) plus basal insulin in medicine department inpatients in real-world clinical practice. We retrospectively enrolled non-critically ill patients with type 2 diabetes with mild to moderate hyperglycaemia and no injectable treatments at home who were treated with a hospital antihyperglycaemic regimen (basal-bolus insulin, or linagliptin-basal insulin) between January 2016 and December 2017. Propensity score was used to match patients in both treatment groups and a comparative analysis was conducted to test the significance of differences between groups. After matched-pair analysis, 227 patients were included per group. No differences were shown between basal-bolus versus linagliptin-basal regimens for the mean daily blood glucose concentration after admission (standardized difference = 0.011), number of blood glucose readings between 100–140 mg/dL (standardized difference = 0.017) and >200 mg/dL (standardized difference = 0.021), or treatment failures (standardized difference = 0.011). Patients on basal-bolus insulin received higher total insulin doses and a higher daily number of injections (standardized differences = 0.298 and 0.301, respectively). Basal and supplemental rapid-acting insulin doses were similar (standardized differences = 0.003 and 0.012, respectively). There were no differences in hospital stay length (standardized difference = 0.003), hypoglycaemic events (standardized difference = 0.018), or hospital complications (standardized difference = 0.010) between groups. This study shows that in real-world clinical practice, the linagliptin-basal insulin regimen was as effective and safe as the standard basal-bolus regimen in non-critical patients with type 2 diabetes with mild to moderate hyperglycaemia treated at home without injectable therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Umpierrez, G. E., Smiley, D., Jacobs, S., Peng, L., Temponi, A., Mulligan, P., Umpierrez, D., Newton, C., Olson, D., & Rizzo, M. (2011) · Diabetes Care · doi:10.2337/dc10-1407 · Cited by 720 · cited 2×
“The use of subcutaneous basal-bolus regimen, which involves the administration of a daily basal insulin dose and rapid-acting insulin before meals, has resulted in improved glycaemic control and reduced risk of complications in the hospital setting [9,10].”
BackgroundUmpierrez, G. E., Smiley, D., Zisman, A., Prieto, L. M., Palacio, A., Ceron, M., Puig, A., & Mejia, R. (2007) · Diabetes Care · doi:10.2337/dc07-0295 · Cited by 671
Management of Hyperglycemia in the Hospital Setting
Inzucchi, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp060094 · Cited by 391 · cited 1×
“Diabetes mellitus is also associated with longer hospital stays and greater incidence of infections, complications and deaths in the hospital [4,6,7].”
BackgroundHypoglycemia-associated mortality is not drug-associated but linked to comorbidities
Boucai, L., Southern, W. N., & Zonszein, J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.07.011 · Cited by 175 · cited 2×
“Additionally, basal-bolus therapy has been linked to a higher risk of clinically important hypoglycaemia, which was reported in 12 to 32% of hospitalized patients with T2D [11,12].”
BackgroundPasquel, F. J., Gianchandani, R., Rubin, D. J., Dungan, K. M., Anzola, I., Gomez, P. C., Peng, L., Hodish, I., Bodnar, T., Wesorick, D., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30402-8 · Cited by 168
Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients
Garg, R., Schuman, B., Hurwitz, S., Metzger, C., & Bhandari, S. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000394 · Cited by 79 · cited 2×
“[19], showed that saxagliptin therapy was no less efficacious than the basal-bolus regimen in regard to glycaemic control in patients who had well-controlled T2D before hospitalization (HbA1c ≤7.”
BackgroundPasquel, F. J., Gomez-Huelgas, R., Anzola, I., Oyedokun, F., Haw, J. S., Vellanki, P., Peng, L., & Umpierrez, G. E. (2015) · Diabetes Care · doi:10.2337/dc15-1835 · Cited by 55 · cited 2×
“patient’s characteristics is of great clinical importance [19,22].”
BackgroundRadhakutty, A., Stranks, J. L., Mangelsdorf, B. L., Drake, S. M., Roberts, G. W., Zimmermann, A. T., Stranks, S. N., Thompson, C. H., & Burt, M. G. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12859 · Cited by 38 · cited 1×
“Use of the subcutaneous basal-bolus regimen with once-daily basal insulin and rapid-acting insulin injections before meals has improved hospital hyperglycaemias and has resulted in reduced risk of complications during the hospitalization [9,10,20].”
Background
Cited by
Management of diabetes and hyperglycaemia in the hospital
Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30381-8 · Cited by 329
Pérez-Belmonte, L. M., Osuna-Sánchez, J., Millán-Gómez, M., López-Carmona, M. D., Gómez-Doblas, J. J., Cobos-Palacios, L., Sanz-Cánovas, J., Barbancho, M. A., Lara, J. P., Jiménez-Navarro, M., et al. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1613672 · Cited by 36
Self-citationBatule, S., Ramos, A., Pérez-Montes de Oca, A., Fuentes, N., Martínez, S., Raga, J., Pena, X., Tural, C., Muñoz, P., Soldevila, B., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102813 · Cited by 13
“Similar findings were reported in a study of non-cardiac surgical and medical patients with T2DM, in which linagliptin was used [12,13].”
ResultInpatient hyperglycemia and transitions of care: A systematic review
Lansang, M. C., Zhou, K., & Korytkowski, M. T. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.016 · Cited by 9
Metadata
- Authors
- Pérez-Belmonte, L., Gómez-Doblas, J., Millán-Gómez, M., López-Carmona, M., Guijarro-Merino, R., Carrasco-Chinchilla, F., De Teresa-Galván, E., Jiménez-Navarro, M., Bernal-López, M., & Gómez-Huelgas, R.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2018-09-11
- Volume
- 7
- Issue
- 9
- Pages
- 271
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2891794449
- Cited by
- 34
- References
- 9
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study). https://app.cochat.ai/papers/10.3390/jcm7090271
- The paper
- Pérez-Belmonte, L., Gómez-Doblas, J., Millán-Gómez, M., López-Carmona, M., Guijarro-Merino, R., Carrasco-Chinchilla, F., De Teresa-Galván, E., Jiménez-Navarro, M., Bernal-López, M., & Gómez-Huelgas, R. (2018). Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study). Journal of Clinical Medicine. https://doi.org/10.3390/jcm7090271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.